Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K/A Current report
- 23.1 Consent of Horne LLP
- 99.1 Audited Financial Statements of Baymedica, Inc. for the Year Ended December 31, 2020
- 99.2 Unaudited Financial Statements of Baymedica, Inc. for the Nine Months Ended September 30, 2021
- 99.3 Unaudited Pro Forma Condensed Combined Financial Information of Inmed Pharmaceuticals Inc
- Download Excel data file
- View Excel data file
INM similar filings
- 10 Feb 22 Regulation FD Disclosure
- 19 Jan 22 InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
- 5 Jan 22 InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
- 22 Dec 21 Audited Financial Statements
- 20 Dec 21 InMed Announces Results of 2021 Annual General Meeting
- 23 Nov 21 Other Events
- 10 Nov 21 InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
Filing view
External links
Exhibit 23.1
Consent of Independent Auditor
We consent to the incorporation by reference in the Registration Statement (Nos. 333-260323 and 333-253912) on Form S-8 of InMed Pharmaceuticals, Inc. of our report dated December 21, 2021, relating to the financial statements of BayMedica, Inc., appearing in this Current Report on Form 8-K/A.
/s/ HORNE LLP
Ridgeland, Mississippi
December 21, 2021